RT Journal Article
T1 Light-Emitting Diode Photobiomodulation After Cerebral Ischemia
A1 Argibay González, Bárbara
A1 Campos Pérez, Francisco
A1 Pérez Mato, María
A1 Vieites Prado, Alba
A1 Correa Paz, Clara
A1 López Arias, Esteban
A1 Silva Candal, Andrés da
A1 Moreno de las Cuevas, Vicente
A1 Montero Orille, Carlos
A1 Sobrino Moreiras, Tomás
A1 Castillo Sánchez, José Antonio
A1 Iglesias Rey, Ramón
K1 Functional recovery
K1 Ischemic stroke
K1 Photobiomodulation therapy
K1 Magnetic resonance imaging
K1 Animal model
K1 Intracerebral hemorrhage
AB Photobiomodulation (PBM) therapy is a promising therapeutic approach for several pathologies, including stroke. The biological effects of PBM for the treatment of cerebral ischemia have previously been explored as a neuroprotective strategy using different light sources, wavelengths, and incident light powers. However, the capability of PBM as a novel alternative therapy to stimulate the recovery of the injured neuronal tissue after ischemic stroke has been poorly explored. The aim of this study was to investigate the low-level light irradiation therapy by using Light Emitting Diodes (LEDs) as potential therapeutic strategy for stroke. The LED photobiomodulation (continuous wave, 830 nm, 0.2–0.6 J/cm2) was firstly evaluated at different energy densities in C17.2 immortalized mouse neural progenitor cell lines, in order to observe if this treatment had any effect on cells, in terms of proliferation and viability. Then, the PBM-LED effect (continuous wave, 830 nm, 0.28 J/cm2 at brain cortex) on long-term recovery (12 weeks) was analyzed in ischemic animal model by means lesion reduction, behavioral deficits, and functional magnetic resonance imaging (fMRI). Analysis of cellular proliferation after PBM was significantly increased (1 mW) in all different exposure times used; however, this effect could not be replicated in vivo experimental conditions, as PBM did not show an infarct reduction or functional recovery. Despite the promising therapeutic effect described for PBM, further preclinical studies are necessary to optimize the therapeutic window of this novel therapy, in terms of the mechanism associated to neurorecovery and to reduce the risk of failure in futures clinical trials.
PB Frontiers Media
YR 2019
FD 2019
LK http://hdl.handle.net/10347/21205
UL http://hdl.handle.net/10347/21205
LA eng
NO Argibay, B., Campos, F., Pérez-Mato, M., Vieites-Prado, A. et al. (2019). Light-Emitting Diode Photobiomodulation After Cerebral Ischemia. "Frontiers in Neurology", vol. 10, 911
NO This project was partially supported by grants from the SpanishMinistry of Economy and Competitiveness (SAF2014-56336-Rand SAF2017-84267-R), Xunta de Galicia (ConselleríaEducación: GRC2014/027 and IN607A2018/3), Instituto deSalud Carlos III (PIE13/00024 and PI17/01103), SpanishResearch Network on Cerebrovascular Diseases RETICSINVICTUSPLUS (RD16/0019), and by the EuropeanUnion FEDER program. Furthermore, TS (CPII17/00027)and FC (CP14/00154) are recipients of research contractsfrom Miguel Servet Program of Instituto de Salud CarlosIII
DS Minerva
RD 24 abr 2026